Transfer pricing rules on AE loans, share application money, and equity infusion: LIBOR benchmarking and no secondary adjustment.

Interest on loans advanced to associated enterprises was treated as an international transaction requiring arm's length benchmarking; LIBOR plus a markup was accepted as the appropriate base, and the treaty argument on unpaid interest did not prevent transfer pricing adjustment. Share application money remitted to an overseas subsidiary was held to be capital in character and not ordinarily re-characterisable as a loan, though abnormal delay in allotment may still require arm's length examination on the facts. Additional equity infusion had to be tested on proper arm's length valuation principles, but a further notional interest adjustment on the same infusion was impermissible as a secondary transfer pricing adjustment.

---

---

Issues: (i) Whether interest on loans advanced to associated enterprises had to be benchmarked at the domestic lending rate or at LIBOR with an appropriate markup, and whether no adjustment could be made on the Mauritius loan because interest was not paid; (ii) Whether share application money remitted to the overseas subsidiary could be treated as an international transaction and re-characterised as a loan for the purpose of notional interest adjustment; (iii) Whether the additional equity infusion in the overseas subsidiary could be brought to tax at nil arm's length value and whether a secondary transfer pricing adjustment on the same capital infusion was permissible.

Issue (i): Whether interest on loans advanced to associated enterprises had to be benchmarked at the domestic lending rate or at LIBOR with an appropriate markup, and whether no adjustment could be made on the Mauritius loan because interest was not paid.

Analysis: The transaction of advancing loans to associated enterprises was held to be an international transaction subject to arm's length pricing under the transfer pricing regime. For benchmarking, the Tribunal followed its earlier decisions and accepted LIBOR as the appropriate base, with a markup to reflect the unsecured nature of the advances. The contention based on commercial expediency did not displace the transfer pricing analysis. As to the Mauritius loan, Article 11 of the treaty was held to deal with taxability of interest when paid and did not exclude the application of transfer pricing provisions to determine arm's length interest on accrued but unpaid consideration.

Conclusion: The arm's length interest had to be determined on the basis of LIBOR plus 2% and the treaty argument did not defeat the transfer pricing adjustment.

Issue (ii): Whether share application money remitted to the overseas subsidiary could be treated as an international transaction and re-characterised as a loan for the purpose of notional interest adjustment.

Analysis: The Tribunal held that share application money is capital in character and cannot ordinarily be re-characterised as an interest-free loan merely because allotment of shares was delayed. At the same time, where there is abnormal delay, an arm's length inquiry may still be relevant to the period of delay, but the proper basis would be what an unrelated applicant would have received for such delay. As the terms and conditions and the exact delay period were not satisfactorily established, the matter required fresh examination.

Conclusion: The adjustment on this account was set aside and the issue was remanded to the Assessing Officer/TPO for fresh consideration.

Issue (iii): Whether the additional equity infusion in the overseas subsidiary could be brought to tax at nil arm's length value and whether a secondary transfer pricing adjustment on the same capital infusion was permissible.

Analysis: The Tribunal held that where the assessee had infused capital in its subsidiary, the valuation exercise had to be tested on a proper arm's length basis, and future-oriented valuation principles were relevant for investment in a 100% subsidiary. However, the revenue's attempt to make a further notional interest adjustment on the same capital infusion amounted to a secondary adjustment over and above the primary adjustment already made. Such a secondary transfer pricing adjustment was not contemplated by the Act.

Conclusion: The matter relating to valuation of the additional equity infusion was restored for reconsideration, and the secondary transfer pricing adjustment was rejected.

Final Conclusion: The assessee obtained relief on the benchmark rate for inter-company loans and on the impermissibility of secondary adjustment, while the share application money issue was sent back for fresh determination.

Ratio Decidendi: In transfer pricing matters, loans to associated enterprises are benchmarked against an arm's length comparable, not by reference to domestic lending rates, share application money is not to be casually re-characterised as a loan, and a secondary adjustment cannot be imposed on the same capital infusion once the primary adjustment has been made.

---